Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$13.89
$10.93
$8.80
$32.71
$618.94M3.4750,770 shs1.01 million shs
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
$11.70
-0.4%
$14.33
$11.67
$67.01
$138.18MN/A1,363 shs2,955 shs
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$3.25
$3.32
$1.26
$4.23
$529.91M3.213.40 million shs4.28 million shs
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$103.89
$99.22
$55.45
$111.29
$573.99M0.94174,506 shs218,130 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
0.00%+14.60%+43.94%+27.78%-27.20%
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
0.00%-15.71%-18.75%-19.09%+1,169,999,900.00%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
0.00%-14.02%-16.24%-0.61%+31.05%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
0.00%+1.83%-0.73%+18.47%-0.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$13.89
$10.93
$8.80
$32.71
$618.94M3.4750,770 shs1.01 million shs
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
$11.70
-0.4%
$14.33
$11.67
$67.01
$138.18MN/A1,363 shs2,955 shs
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$3.25
$3.32
$1.26
$4.23
$529.91M3.213.40 million shs4.28 million shs
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$103.89
$99.22
$55.45
$111.29
$573.99M0.94174,506 shs218,130 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
0.00%+14.60%+43.94%+27.78%-27.20%
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
0.00%-15.71%-18.75%-19.09%+1,169,999,900.00%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
0.00%-14.02%-16.24%-0.61%+31.05%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
0.00%+1.83%-0.73%+18.47%-0.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
2.64
Moderate Buy$19.7041.83% Upside
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
1.00
SellN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
2.57
Moderate Buy$15.50376.92% Upside
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
1.67
Reduce$94.00-9.52% Downside

Current Analyst Ratings Breakdown

Latest BRBI, BBNX, MLAB, and CABA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2026
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
UpgradeSell (E)Sell (D-)
6/3/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
DowngradeSell (D+)Sell (D)
6/3/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Reiterated RatingBuy
5/27/2026
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Lower Price TargetBuy$19.00 ➝ $17.00
5/22/2026
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
DowngradeSell (E+)Sell (E)
5/18/2026
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Lower Price TargetNeutral$23.00 ➝ $11.00
5/15/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Boost Price TargetEqual Weight$2.00 ➝ $4.00
5/4/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
Reiterated RatingSell (D+)
5/4/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Reiterated RatingOverweight$30.00
4/22/2026
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Lower Price TargetOutperform$25.00 ➝ $24.00
4/22/2026
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Lower Price TargetBuy$22.00 ➝ $20.00
(Data available from 6/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$100.25M6.17N/AN/A$6.53 per share2.13
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/AN/AN/AN/AN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/A$1.16 per shareN/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$249.13M2.30$11.78 per share8.82$33.71 per share3.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-$73.20M-$1.51N/AN/AN/A-60.27%-23.00%-20.55%N/A
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$167.86M-$1.96N/AN/AN/AN/A-131.58%-96.46%8/6/2026 (Estimated)
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$6.71M$1.2086.58N/AN/A2.69%20.96%8.78%8/4/2026 (Estimated)

Latest BRBI, BBNX, MLAB, and CABA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/27/2026Q4 2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$1.78$1.53-$0.25-$0.75$65.21 million$63.72 million
5/14/2026Q1 2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A
5/7/2026Q1 2026
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/A$0.09N/A$0.09N/A$25.95 million
4/21/2026Q1 2026
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-$0.53-$0.49+$0.04-$0.49N/A$27.63 million
3/31/2026Q1 2026
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/A$0.09N/A$0.09N/A$25.95 million
3/23/2026Q4 2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.45-$0.40+$0.05-$0.40N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/AN/AN/AN/AN/A
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
$0.514.36%N/AN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/AN/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$0.640.62%N/A53.33%N/A

Latest BRBI, BBNX, MLAB, and CABA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/2/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
quarterly$0.160.63%5/29/20265/29/20266/15/2026
5/8/2026
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
quarterly$0.14704.58%5/19/20265/19/20266/5/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
10.69
9.67
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/AN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
2.95
2.95
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
0.78
1.72
1.29

Institutional Ownership

CompanyInstitutional Ownership
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
90.60%

Insider Ownership

CompanyInsider Ownership
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
5.30%
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
6.44%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
4.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
29444.56 million42.20 millionN/A
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/A11.81 millionN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
50163.05 million152.55 millionOptionable
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
6805.53 million5.25 millionNot Optionable

Recent News About These Companies

Mesa Laboratories declares a $0.16 dividend
Mesa Laboratories: Hard To Set The Right Diagnosis
Mesa Laboratories Names New CEO for Next Phase

New MarketBeat Followers Over Time

Media Sentiment Over Time

Beta Bionics stock logo

Beta Bionics NASDAQ:BBNX

$13.89 0.00 (0.00%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$13.55 -0.34 (-2.45%)
As of 04:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

BR Biopharma stock logo

BR Biopharma NASDAQ:BRBI

$11.70 -0.05 (-0.43%)
Closing price 06/5/2026 03:58 PM Eastern
Extended Trading
$11.72 +0.02 (+0.19%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.

Cabaletta Bio stock logo

Cabaletta Bio NASDAQ:CABA

$3.25 0.00 (0.00%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$3.30 +0.05 (+1.54%)
As of 06:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Mesa Laboratories stock logo

Mesa Laboratories NASDAQ:MLAB

$103.89 0.00 (0.00%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$103.47 -0.42 (-0.40%)
As of 04:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.